SCHEMBL19743079

SCHEMBL19743079

CC(C)(C)OC(=O)[C@H](CCCCNC(=O)CCCc1ccc([Sn](C)(C)C)cc1)NC(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ALB P02768 3/20 0.52
▸ FOLH1 Q04609 17/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19743081 1.00 ALB (0.52) ALBFOLH1
SCHEMBL19743137 0.97 ALB (0.48) ALBFOLH1
SCHEMBL19743136 0.97 ALB (0.48) ALBFOLH1
SCHEMBL19743135 0.96 FOLH1 (0.50) ALBFOLH1
SCHEMBL19743134 0.96 FOLH1 (0.50) ALBFOLH1
SCHEMBL19743102 0.93 FOLH1 (0.46) ALBFOLH1
SCHEMBL19743084 0.91 FOLH1 (0.51) FOLH1
SCHEMBL19743083 0.91 FOLH1 (0.51) FOLH1
SCHEMBL31317984 0.91 ALB (0.45) ALBFOLH1
SCHEMBL19743095 0.89 ALB (0.57) ALBFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210137860-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL CORNELL UNIVERSITY (US) 2021-05-13 — — US disclosed
US-10716772-B2 Double targeted constructs to affect tumor kill CORNELL UNIVERSITY (US) 2020-07-21 — — US disclosed
US-20190142770-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL CORNELL UNIVERSITY 2019-05-16 — — US disclosed
US-10179117-B2 Double targeted constructs to affect tumor kill CORNELL UNIVERSITY (US) 2019-01-15 — — US disclosed
US-20170368005-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL CORNELL UNIVERSITY 2017-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210137860-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL PSMA2, FOLH1, KLK3 ALB 1812/4885FOLH1 2/4885
US-10716772-B2 Double targeted constructs to affect tumor kill PSMA2, FOLH1, KLK3 ALB 1812/4885FOLH1 2/4885
US-20170368005-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL PSMA2, FOLH1, KLK3 ALB 1812/4885FOLH1 2/4885
US-20190142770-A1 DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL PSMA2, FOLH1, KLK3 ALB 1812/4885FOLH1 2/4885
US-10179117-B2 Double targeted constructs to affect tumor kill PSMA2, FOLH1, KLK3 ALB 1812/4885FOLH1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback